Canadian glaucoma study: 2. Risk factors for the progression of open-angle glaucoma

Archives of Ophthalmology

Volumn 126, Issue 8, 2008, Pages 1030-1036

  Chauhan, Balwantray C ^a   Mikelberg, Frederick S ^b   Balaszi, A Gordon ^c   LeBlanc, Raymond P ^a   Lesk, Mark R ^d   Trope, Graham E ^e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD CLOTTING DISORDER; CANADA; CLINICAL TRIAL; COMPUTER ASSISTED PERIMETRY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OPHTHALMOSCOPY; PRIORITY JOURNAL; SEX DIFFERENCE; VASOSPASM; VISUAL FIELD DEFECT;

AGED; BLOOD FLOW VELOCITY; DISEASE PROGRESSION; FEMALE; FINGERS; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; OPTIC NERVE DISEASES; PERIMETRY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VISION DISORDERS; VISUAL FIELDS;

EID: 49449109010     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.8.1030     Document Type: Article

References (35)

1. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714-720.
2. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121(1):48-56.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
4. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126(4):487-497.
5. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
6. Canadian Glaucoma Study Group. Canadian Glaucoma Study, 1: study design, baseline characteristics, and preliminary analyses [published correction appears in Can J Ophthalmol. 2007;42(4):647]. Can J Ophthalmol. 2006;41(5):566-575.
7. Drance SM, Douglas GR, Wijsman K, Schulzer M, Britton RJ. Response of blood flow to warm and cold in normal and low-tension glaucoma patients. Am J Ophthalmol. 1988;105(1):35-39.
8. Heijl A, Lindgren G, Lindgren A, et al. Extended empirical statistical package for evaluation of single and multiple fields: Statpac 2. In: Mills RP, Heijl A, eds. Perimetry Update 1990/1. New York, NY: Kugler & Ghedini; 1991:303-315.
9. Schulzer M, Drance SM, Carter CJ, Brooks DE, Douglas GR, Lau W. Biostatistical evidence for two distinct chronic open angle glaucoma populations. Br J Ophthalmol. 1990;74(4):196-200.
10. Ishida K, Yamamoto T, Kitazawa Y. Clinical factors associated with progression of normal-tension glaucoma. J Glaucoma. 1998;7(6):372-377.
11. Carter CJ, Brooks DE, Doyle DL, Drance SM. Investigations into a vascular etiology for low-tension glaucoma. Ophthalmology. 1990;97(1):49-55.
12. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440.
13. Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. Ophthalmology. 2001;108(2):247-253.
14. Hulsman CA, Westendorp IC, Ramrattan RS, et al. Is open-angle glaucoma associated with early menopause? Am J Epidemiol. 2001;154(2):138-144.
15. Lee AJ, Mitchell P, Rochtchina E, Healey PR. Female reproductive factors and open angle glaucoma. Br J Ophthalmol. 2003;87(11):1324-1328.
16. Harris A, Harris M, Biller J, et al. Aging affects the retrobulbar circulation differently in women and men. Arch Ophthalmol. 2000;118(8):1076-1080.
17. Harris-Yitzhak M, Harris A, Ben-Refael Z, Zarfati D, Garzozi HJ, Martin BJ. Estrogen-replacement therapy: effects on retrobulbar hemodynamics. Am J Ophthalmol. 2000;129(5):623-628.
18. Battaglia C, Mancini F, Regnani G, Persico N, Volpe A, De Aloysio D. Hormone therapy and ophthalmic artery blood flow changes in women with primary open-angle glaucoma. Menopause. 2004;11(1):69-77.
19. Bengtsson B. Aspects of the epidemiology of chronic glaucoma. Acta Ophthalmol Suppl. 1981;(146):1-48.
20. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands: The Rotterdam Study. Ophthalmology. 1994;101(11):1851-1855.
21. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham Eye Study, II: association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol. 1977;106(1):33-41.
22. Leske MC, Connell AM, Schachat AP, Hyman L. The Barbados Eye Study: prevalence of open angle glaucoma. Arch Ophthalmol. 1994;112(6):821-829.
23. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. Ophthalmology. 1996;103(10):1661-1669.
24. Shiose Y, Kitazawa Y, Tsukahara S, et al. Epidemiology of glaucoma in Japan - a nationwide glaucoma survey. Jpn J Ophthalmol. 1991;35(2):133-155.
25. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Family history and risk of primary open angle glaucoma. Arch Ophthalmol. 1994;112(1):69-73.
26. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am. 1997;81(1):151-177.
27. Muir KW. Anticardiolipin antibodies and cardiovascular disease. J R Soc Med. 1995;88(8):433-436.
28. Levine SR, Brey RL, Tilley BC, et al; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576-584.
29. Kremmer S, Kreuzfelder E, Klein R, et al. Antiphosphatidylserine antibodies are elevated in normal tension glaucoma. Clin Exp Immunol. 2001;125(2):211-215.
30. Tsakiris DA, Osusky R, Kaiser HJ, Mueri R, Flammer J, Marbet GA. Lupus anticoagulants/anticardiolipin antibodies in patients with normal tension glaucoma. Blood Coagul Fibrinolysis. 1992;3(5):541-545.
31. Katz J, Congdon N, Friedman DS. Methodological variations in estimating apparent progressive visual field loss in clinical trials of glaucoma treatment. Arch Ophthalmol. 1999;117(9):1137-1142.
32. Lee AC, Sample PA, Blumenthal EZ, Berry C, Zangwill L, Weinreb RN. Infrequent confirmation of visual field progression. Ophthalmology. 2002;109(6):1059-1065.
33. Vesti E, Johnson CA, Chauhan BC. Comparison of different methods for detecting glaucomatous visual field progression. Invest Ophthalmol Vis Sci. 2003;44(9):3873-3879.
34. Chauhan BC. Choosing endpoints in clinical studies and trials. Eye. December 2007;21(suppl 1s):S34-S37. doi:10.1038/sj.eye.6702886.
35. Artes PH, Nicolela MT, LeBlanc RP, Chauhan BC. Visual field progression in glaucoma: total versus pattern deviation analyses. Invest Ophthalmol Vis Sci. 2005;46(12):4600-4606.